Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05903183 | A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age | PHASE2 | COMPLETED | 264 | — | — | May 1, 2023 | Oct 1, 2024 | Dec 4, 2025 | - | — |
| Name | Type | Description |
|---|---|---|
| IVX-A12 | BIOLOGICAL | IVX-A12 without adjuvant |
| Placebo | BIOLOGICAL | Diluent |